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Milk and milk products contribute approximately 22 % of the nation’s saturated fat (SFA) intake. Recently, the role of dairy and its
SFA composition and link to cardiovascular disease (CVD) has been analysed(1), suggesting a beneficial action of this food group on
reducing cardiovascular risk in high-risk groups(2,3). The aim of this study was to examine the effects of 4 weeks full-fat cheese on
circulating lipoprotein fractions, blood pressure and arterial stiffness in healthy adults.
Participants were recruited in the city of Chester, UK. Those meeting entry criteria of: 18–65 years of age, not taking antihyperch-
olesterolaemic or antihypertensive medication took part in the study. Participants were randomised to receive either 50 g of a full-fat
Red Leicester (FFC) or placebo (virtually zero fat Cheddar cheese, ZFC) per day for 4 weeks. Anthropometry, blood pressure, bra-
chial and aortic augmentation index (BAIX and AAIX, respectively), pulse-wave velocity (PWV) and a full lipid profile were deter-
mined at baseline and post-intervention. Participants were asked to keep a 3-day food diary prior to and for the last 3 days of the
protocol. All procedures were approved by the Faculty of Medicine, Dentistry and Life Sciences Research Ethics Committee at
the University of Chester.
Eighty-six (86) individuals completed the study (43 per group). No significant changes were observed in any measured parameter
(Table 1). Both ZFC and FFC groups showed a significant increase in calcium intake during the course of the study (1002·1 ± 639·1
mg to 1815·0 ± 1340·1 mg and 1219·6 ± 1169·1 mg 1845·8 ± 1463·2 mg, P < 0·001, respectively) showing good adherence to the
protocol.
In conclusion, these results suggest that inclusion of 50 g full fat cheese into the diet of a healthy population does not impact nega-
tively on traditional CVD risk markers. Future strategies to reduce SFA intake should focus on – and acknowledge the importance of
the source – of SFA in the diet.
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Table 1. Baseline (T0) and follow-up (T1) measurements
Zero fat cheese (ZFC) Full fat cheese (FFC)
Time Time ×GroupT0 SD T1 SD T0 SD T1 SD
Weight (Kg) 73·7 16·7 74·5 16·5 70·6 15·1 70·3 14·2 P = 0·878 P = 0·850
LDL (mmol/L) 2·2 0·8 2·3 0·6 2·4 0·8 2·4 0·9 P = 0·307 P = 0·728
HDL (mmol/L) 1·5 0·4 1·4 0·4 1·4 0·3 1·4 0·3 P = 0·841 P = 0·345
AIX (%) 13·7 11·2 10·8 16·7 14·5 12·8 12·0 9·4 P = 0·242 P = 0·525
BAIX (%) −25·5 50·1 −3·3 58·0 −18·6 48·8 −6·6 54·1 P = 0·052 P = 0·751
PWV (m/s) 5·8 0·9 6·1 1·3 5·9 1·1 5·9 0·9 P = 0·149 P = 0·691
T0, baseline; T1 follow-up, LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein-cholesterol; BAIX, brachial augmentation index; AAIX,
aortic augmentation index; PWV, pulse-wave velocity. Data show mean ± SD.
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